MTTI is a clinical research company transforming the lives of patients battling serious and life-threatening diseases.
MTTI’s lead drug is EBTATE, a selective radiotherapeutic targeting neuroendocrine tumors.
The MTTI team is composed of experienced executives from multinational pharmaceutical companies, each with a proven track record.
As Nukleon, we serve as the sole authorized distributor of MTTI in the Turkish market.
For more information, you can visit mtarget.com ↗.